Meghara Walsh

1.6k total citations · 1 hit paper
20 papers, 1.1k citations indexed

About

Meghara Walsh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Meghara Walsh has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Meghara Walsh's work include Renal cell carcinoma treatment (16 papers), Renal and related cancers (10 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Meghara Walsh is often cited by papers focused on Renal cell carcinoma treatment (16 papers), Renal and related cancers (10 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Meghara Walsh collaborates with scholars based in United States, Canada and United Kingdom. Meghara Walsh's co-authors include Toni K. Choueiri, M. Dror Michaelson, Joel Picus, Shaker R. Dakhil, Olwen Hahn, Michael J. Morris, Daniel J. George, Susan Halabi, Eric J. Small and Thomas Olencki and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Meghara Walsh

20 papers receiving 1.1k citations

Hit Papers

Cabozantinib Versus Sunit... 2017 2026 2020 2023 2017 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
    2017 507 citations Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Meghara Walsh United States 11 833 515 499 379 290 20 1.1k
Lionnel Geoffrois France 21 844 1.0× 504 1.0× 595 1.2× 268 0.7× 675 2.3× 90 1.6k
Teodoro Sava Italy 18 554 0.7× 292 0.6× 502 1.0× 231 0.6× 282 1.0× 69 1.1k
Lisa Pickering United Kingdom 17 705 0.8× 603 1.2× 378 0.8× 384 1.0× 234 0.8× 74 1.2k
M. Neil Reaume Canada 18 642 0.8× 302 0.6× 461 0.9× 218 0.6× 234 0.8× 66 1.1k
Philippe Barthélémy France 20 752 0.9× 481 0.9× 765 1.5× 276 0.7× 599 2.1× 123 1.6k
C. Sternberg Italy 16 606 0.7× 210 0.4× 397 0.8× 228 0.6× 225 0.8× 67 1.1k
Aline Guillot France 16 692 0.8× 426 0.8× 315 0.6× 330 0.9× 206 0.7× 62 1.0k
Stephen B. Riggs United States 17 989 1.2× 674 1.3× 324 0.6× 350 0.9× 408 1.4× 50 1.4k
Alessia Mennitto Italy 19 479 0.6× 271 0.5× 549 1.1× 225 0.6× 212 0.7× 59 1.0k
Q.D. Trinh United States 11 535 0.6× 199 0.4× 314 0.6× 120 0.3× 212 0.7× 24 743

Countries citing papers authored by Meghara Walsh

Since Specialization
Citations

This map shows the geographic impact of Meghara Walsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meghara Walsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meghara Walsh more than expected).

Fields of papers citing papers by Meghara Walsh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meghara Walsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meghara Walsh. The network helps show where Meghara Walsh may publish in the future.

Co-authorship network of co-authors of Meghara Walsh

This figure shows the co-authorship network connecting the top 25 collaborators of Meghara Walsh. A scholar is included among the top collaborators of Meghara Walsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meghara Walsh. Meghara Walsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burns, Kathleen H., Nancy P. Moldawer, Meghara Walsh, et al.. (2023). The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma. Seminars in Oncology Nursing. 40(1). 151545–151545. 2 indexed citations
2.
3.
George, Daniel J., Colin Hessel, Susan Halabi, et al.. (2019). Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. The Oncologist. 24(11). 1497–1501. 20 indexed citations
4.
McKay, Rana R., Bradley A. McGregor, Kathryn P. Gray, et al.. (2019). Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. Journal of Clinical Oncology. 37(7_suppl). 548–548. 19 indexed citations
5.
McKay, Rana R., Dominick Bossé, Kathryn P. Gray, et al.. (2018). Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research. 24(17). 4081–4088. 26 indexed citations
6.
McKay, Rana R., Lillian Werner, Atish D. Choudhury, et al.. (2018). Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. Journal of Medical Internet Research. 21(5). e12044–e12044. 2 indexed citations
7.
8.
Choueiri, Toni K., M. Dror Michaelson, Edwin M. Posadas, et al.. (2018). An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. The Oncologist. 24(2). 202–210. 22 indexed citations
9.
10.
Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597. 507 indexed citations breakdown →
11.
12.
Bossé, Dominick, Kathryn P. Gray, M. Dror Michaelson, et al.. (2017). Pazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm). Annals of Oncology. 28. v299–v299. 2 indexed citations
13.
McKay, Rana R., Dylan J. Martini, Raphael Brandão Moreira, et al.. (2017). Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 35(6_suppl). 467–467. 7 indexed citations
14.
15.
McKay, Rana R., Guillermo de Velasco, Lillian Werner, et al.. (2016). A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies. Cancer. 122(15). 2389–2398. 13 indexed citations
16.
McKay, Rana R., Lillian Werner, Lauren C. Harshman, et al.. (2015). A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. Journal of Clinical Oncology. 33(15_suppl). 4559–4559. 2 indexed citations
17.
Choueiri, Toni K., M. Dror Michaelson, Edwin M. Posadas, et al.. (2015). A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 33(7_suppl). 426–426. 9 indexed citations
18.
Choueiri, Toni K., Susanna Jacobus, Joaquim Bellmunt, et al.. (2014). Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology. 32(18). 1889–1894. 184 indexed citations
19.
Choueiri, Toni K., Edwin M. Posadas, Guru Sonpavde, et al.. (2014). A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 32(15_suppl). e15562–e15562. 5 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lionnel Geoffrois Breakdown of academic impact, for papers by Teodoro Sava Breakdown of academic impact, for papers by Lisa Pickering Breakdown of academic impact, for papers by M. Neil Reaume Breakdown of academic impact, for papers by Philippe Barthélémy Breakdown of academic impact, for papers by C. Sternberg Breakdown of academic impact, for papers by Aline Guillot Breakdown of academic impact, for papers by Stephen B. Riggs Breakdown of academic impact, for papers by Alessia Mennitto Breakdown of academic impact, for papers by Q.D. Trinh
Rankless by CCL
2026